Results 131 to 140 of about 6,218 (156)

Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment

Clinical Infectious Diseases, 2023
Antoine Chaillon, Tariq Rana, Aaron Carlin   +2 more
exaly  

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

Clinical Infectious Diseases, 2023
Rockib Uddin, Jonathan Li, Jacob Lemieux   +2 more
exaly  

Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment

Organic Process Research and Development, 2023
Javier Magano, Kaitlyn Gray, Aran Hubbell   +2 more
exaly  

Carfilzomib/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS

Pharmaceuticals, 2022

exaly  

Nirmatrelvir+ritonavir/tozinameran

Reactions Weekly, 2023
openaire   +1 more source

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19

Open Forum Infectious Diseases, 2022
Michael Usher, , Nicolas Hoertel
exaly  

Nirmatrelvir/Ritonavir/Tacrolimus

Reactions Weekly
  +6 more sources

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir

Bioorganic and Medicinal Chemistry Letters, 2022
Gottfried Otting, Christoph Nitsche, Sven Ullrich   +2 more
exaly  

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

International Journal of Antimicrobial Agents, 2023
Iker Falces-Romero, Francesco Marchesi, Oliver A Cornely   +2 more
exaly